• Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses
• Phase 1/2 study to enroll ~500 healthy adults, with topline results expected by 2028
• We aim to build a universal Sarbecovirus vaccine platform to proactively address future pandemics

SEONGNAM, South Korea, Oct. 15, 2025 -- SK bioscience announced that it has submitted a Phase 1/2 clinical trial application in Australia for GBP511, a universal coronavirus vaccine (pan-sarbecovirus vaccine) candidate.

Sarbecoviruses, a subgenus of coronaviruses, include SARS-CoV-2 (COVID-19), the original SARS virus, and related variants. GBP511 is designed to provide broad protection across the sarbecovirus family, moving beyond the strain-specific approach of existing COVID-19 vaccines.

The trial will enroll approximately 500 healthy adults aged 18 and older in Australia, and will evaluate safety and cross-reactive immunogenicity, with topline results expected by 2028.

The GBP511 program was initiated in 2021 with support from the Coalition for Epidemic Preparedness Innovations (CEPI), which provided funding of approximately USD 65 million to advance preclinical research, early-stage clinical trials, and manufacturing process development.

GBP511 builds on SK bioscience's recombinant protein platform, which was previously validated through the approval of SKYCovione™—the world's first computer-generated vaccine and Korea's first domestically developed COVID-19 vaccine—in 2022. The candidate also incorporates the self-assembling nanoparticle design technology from the UW Medicine's Institute for Protein Design (IPD). SKYCovione demonstrated favorable safety and immunogenicity in global studies, laying the foundation for broader coronavirus vaccine development.

The World Health Organization (WHO) highlighted in its 2022 report "Why do we need a pan-sarbecovirus vaccine?" that the repeated emergence of variants, waning immunity, reinfection risk, and zoonotic spillover emphasize the urgent need for a broad-spectrum coronavirus vaccine.

According to Coherent Market Insights, the global COVID-19 vaccine market is projected to be worth USD 50.6 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.4% to reach USD 83.4 billion by 2032. This outlook underscores the potential of next-generation vaccines like GBP511 to drive future demand.

"Even as the COVID-19 pandemic has eased, related viruses continue to evolve and pose global health risks," said Jaeyong Ahn, CEO of SK bioscience. "GBP511 is designed to overcome the limitations of strain-specific vaccines by targeting the entire sarbecovirus family. With this approach, we aim to strengthen pandemic preparedness and safeguard against future outbreaks."

Beyond GBP511, SK bioscience is advancing multiple pandemic-preparedness programs. These include an mRNA-based Japanese encephalitis vaccine currently in Phase 1/2 global studies with CEPI, and a government-backed avian influenza vaccine program launched earlier this year. Together, these initiatives strengthen SK bioscience's pipeline for responding to future infectious disease threats.

About SK bioscience

SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions.

- SK bioscience Website
- SK bioscience Linkedin

Contact
SK bioscience Communications Team
Changhyun Jin (jin99@sk.com)
Muncheol. Kim (MC_kim@sk.com)